Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Current Deferred Revenue (2023 - 2025)

Beta Bionics (BBNX) has disclosed Current Deferred Revenue for 3 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 65.81% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 65.81% year-over-year, with the annual reading at $1.6 million for FY2025, 65.81% up from the prior year.
  • Current Deferred Revenue hit $1.6 million in Q4 2025 for Beta Bionics, up from $1.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.6 million in Q4 2025 to a low of $87000.0 in Q4 2023.
  • Historically, Current Deferred Revenue has averaged $1.0 million across 3 years, with a median of $1.0 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 979.31% in 2024 and later surged 65.81% in 2025.
  • Year by year, Current Deferred Revenue stood at $87000.0 in 2023, then surged by 979.31% to $939000.0 in 2024, then soared by 65.81% to $1.6 million in 2025.
  • Business Quant data shows Current Deferred Revenue for BBNX at $1.6 million in Q4 2025, $1.3 million in Q3 2025, and $1.1 million in Q2 2025.